Manish K. Aghi MD, PhD

Assistant Professor in Residence of Neurological Surgery

Principal Investigator, Brain Tumor Research Center

Attending Neurosurgeon, California Center for Pituitary Disorders

 

Dr. Aghi is a neurosurgeon-scientist specializing in adult brain tumors. He is experienced in the surgical treatment of glioneuronal neoplasms, meningiomas, and pituitary tumors. He has experience with minimally invasive endoscopic approaches to the anterior skull base, and intraoperative mapping of brain function to optimize tumor resection. Dr. Aghi has extensive basic science research interests, including glioma angiogenesis and the use of oncolytic viruses to treat glioblastoma.  Read about Dr. Aghi's basic science research laboratory in the UCSF Brain Tumor Research Center (BTRC) here.

Education, Training, and Previous Positions

1993: BS, MS, Stanford University

2000: MD, PhD, Harvard Medical School

2000-2007: Residency, Neurological Surgery, Massachusetts General Hospital

2007: Instructor, Department of Neurological Surgery, Massachusetts General Hospital and Harvard Medical School

2008-present: Assistant Professor in Residence, Department of Neurological Surgery, UCSF

Selected Professional Memberships and Appointments

Society for Neuro-Oncology

Pituitary Network Association (PNA)

American Association of Neurological Surgeons (AANS)

Congress of Neurological Surgeons (CNS)

AANS and CNS, Joint Section for Tumors

Selected Honors and Awards

2004: Preuss Resident Research Award, American Association of Neurologic Surgeons and Congress of Neurological Surgeons

2005: Ronald L. Bittner Award, American Association of Neurologic Surgeons (AANS)

2005: William Scoville Resident Research Award, New England Neurosurgery meeting

2005: Congress of Neurologic Surgeons (CNS) Resident Research Award

2005: American Academy of Neurologic Surgeons Resident Research Award

2006: Mahaley Award, American Association of Neurologic Surgeons

2006: Integra Foundation Award, Congress of Neurologic Surgeons

2007: Synthes Skull Base Award, Congress of Neurologic Surgeons
2009: American Brain Tumor Association (ABTA) Young Investigator Award, Congress of Neurologic Surgeons 

Selected Recent Publications

Tate MC, Aghi MK.  Biology of angiogenesis and invasion in glioma.  Neurotherapeutics 2009; 6: 447-457.

Aghi MK, Blevins LS Jr.  Recent advances in the treatment of acromegaly.  Curr Opin Endocrinol Diabetes Obes 2009; 16: 304-307.

Aghi MK, Batchelor TT, Louis DN, Barker FG, Curry WT.  Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q.  Journal of Neuro-oncology 2009; 93: 115-120. 

Aghi MK, Petit J, Chapman P, Loeffler J, Klibanski A, Biller BMK, Swearingen B.  Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery.  Clin Neurosurg 2009; 55: 141-144.

Aghi MK, Carter BS, Cosgrove GR, Ojemann RS, Amin-Hanjani S, Martuza RL, Curry WT, Barker FG.  Long-term recurrence rates of atypical meningiomas after gross total resection without or with postoperative adjuvant radiation.  Neurosurgery 2009; 64: 56-60.

Aghi MK, Chiocca EA.  Phase Ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.  Mol Ther 2009; 17: 8-9. 

Aghi MK, Liu TC, Rabkin S, Martuza RL. Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus. Mol Ther 2008; 17: 51-56. 

Aghi MK. Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrin Metab 2008;4(10):560-8.

Aghi M, Visted T, Depinho RA, Chiocca EA.Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008;27(30):4249-54.

Aghi MK, Eskandar EN, Carter BS, Curry WT Jr, Barker FG 2nd. Increased prevalence of obesity and obesity-related postoperative complications in male meningioma patients. Clin Neurosurg 2007;54:236-40.

Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007;67(2):440-4.

Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.J Natl Cancer Inst 2006;98(1):38-50.
 
Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006;66(18):9054-64.
 
Aghi M, Kluwe L, Webster MT, Jacoby LB, Barker FG 2nd, Ojemann RG, Mautner VF, MacCollin M. Unilateral vestibular schwannoma with other NF2-related tumors: clinical and molecular study of a unique phenotype.  J Neurosurg 2006;104(2):201-7.
 
Aghi M, Chiocca EA. Gene therapy for glioblastoma. Neurosurg Focus 2006;20(4):E18.
 
Aghi M, Barker FG 2nd. Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg 2006;19:80-96.
 
Aghi M, Kiehl TR, Brisman JL. Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature [Review]. J Neurooncol 2005;75(2):149-55.
 
Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11(24 Pt 1):8600-5.
 
Aghi M, Chiocca EA. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther 2005;12(6):994-1005.
 
Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005;24(52):7802-16.
 
Aghi M, Rabkin S. Viral vectors as therapeutic agents for glioblastoma. Curr Opin Mol Ther 2005;7(5):419-30.
 
Hoh BL, Aghi M, Pryor JC, Ogilvy CS. Heparin-induced thrombocytopenia Type II in subarachnoid hemorrhage patients: incidence and complications. Neurosurgery 2005;57(2):243-8; discussion 243-8.
 
Aghi M, Coumans JV, Brisman JL. Subarachnoid hematoma, hydrocephalus, and aseptic meningitis resulting from a high cervical myelogram. J Spinal Disord Tech 2004;17(4):348-51. Erratum in: J Spinal Disord Tech 2005;18(2):207.
 
Aghi M, Chiocca EA. Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review. Cancer Invest 2003;21(2):278-92.
 
Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000;2(3):148-64.
 
Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999;59(16):3861-5.
 
Aghi M, Kramm CM, Breakefield XO. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999;91(14):1233-41.
 
Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998;90(5):370-80.